Adult Conditions

When used as directed, TYLENOL® is an appropriate pain relief choice for many patients.

NSAIDS may interfere with a variety of treatment therapies

54%* of your patients may be at risk for adverse events if you’re not considering their comorbidities when recommending an analgesic.1

NSAIDs may interfere with some medications used for cardiovascular disease.2-4 NSAIDs also may not be suitable for certain osteoarthritis (OA) patients who have certain comorbidities.5

Recommend TYLENOL® with confidence

An established safety profile and proven analgesic efficacy make TYLENOL® an appropriate choice for many patients.

Updated NSAID warnings: help your patients understand risks

The U.S. Food and Drug Administration (FDA) required an update to the Drug Facts labeling of all adult and pediatric non-aspirin OTC nonsteroidal anti-inflammatory drugs (NSAIDs), for example Motrin®, Advil®, and Aleve® products. These strengthen and expand existing warnings relating to the risk of heart attack and stroke associated with NSAIDs.6

TYLENOL® does not have a cardiovascular risk warning on its label

Download the NSAID Warning Comparison Guide for more information.


For patients in pain

Why is TYLENOL® an effective analgesic?

For patients with certain comorbidities

TYLENOL® may be a more appropriate analgesic choice than NSAIDs2,3,7-11

*Percentage of consumers age 45+ who have high blood pressure, kidney disease, or are taking low-dose aspirin for heart health and thus may not be appropriate to use NSAIDs.

REFERENCES: 1. Data on file. Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division. Fort Washington, PA; 2017. 2. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345(25):1809-1817. 3. Elliott WJ. Drug interactions and drugs that affect blood pressure. J Clin Hypertens. 2006;8(10):731-737. 4. Radack KL, Deck CC, Bloomfield SS. Ibuprofen interferes with the efficacy of antihypertensive drugs. Ann Intern Med. 1987;107:628-635. 5. American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc. 2009;57(8):1331-1346.6. U.S. Food and Drug Administration. FDA strengthens warning of heart attack and stroke risk for non-steroidal anti-inflammatory drugs. Accessed January 12, 2018. 7. Horn JR, Hansten PD. NSAIDs and antihyperintensive agents. Pharmacy Times. Published April 1, 2006. Accessed January 5, 2017. 8. Hoftiezer JW, O’Laughlin JC, Ivey KJ. Effects of 24 hours of aspirin, Bufferin, paracetamol and placebo on normal human gastroduodenal mucosa. Gut. 1982;23(8):692-697. 9. Blot WJ, McLaughlin JK. Over the counter non-steroidal anti-inflammatory drugs and risk of gastrointestinal bleeding. J Epidemiol Biostat. 2000;5(2):137-142. 10. Frech EJ, Go MF. Treatment and chemoprevention of NSAID-associated gastrointestinal complications. Ther Clin Risk Manag. 2009;5(1):65-73. 11. Prescott LF, Speirs GC, Critchley JA, Temple RM, Winney RJ. Paracetamol disposition and metabolite kinetics in patients with chronic renal failure. Eur J Clin Pharmacol. 1989;36(3):291-297. 12. Martin U, Temple RM, Winney RJ, Prescott LF. The disposition of paracetamol and the accumulation of its glucuronide and sulphate conjugates during multiple dosing in patients with chronic renal failure. Eur J Clin Pharmacol. 1991;41(1):43-46.